Open Orphan Investor Presentation Feb 2020

Open Orphan plc (LON:ORPH) Co-Founder and Executive Chairman Cathal Friel talks us though the Feb 2020 Investor Presentation.

Open Orphan was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). In June 2019 Open Orphan acquired AIM-listed Venn Life Sciences plc in a reverse take-over and in January 2020 completed a merger with hVIVO plc.

Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth markets.

You might also enjoy reading  Open Orphan positive results received from human challenge study
Find more news, interviews, share price & company profile here for:
Open Orphan plc

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Open Orphan
Open Orphan Investor Presentation Feb 2020

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions